Introduction {#sec0001}
============

A severe respiratory coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) has emerged as a pandemic at the end of 2019 ([@bib0008]; [@bib0053]). By July 2020, SARS-CoV-2 has affected more than 200 territories, infecting more than 13 million individuals and causing more than 0.5 million deaths (WHO, Situation Report--177). COVID-19 has marked the history with third life-threatening coronavirus epidemic into the human population during 21^st^ century ([@bib0009]). By 7^th^ January, 2020, Chinese scientists released the sequenced SARS-CoV-2 genome for the identification and development of potential candidates against COVID-19 by computational methods and other therapeutic techniques ([@bib0027]).

The SARS-CoV-2 is a β-coronavirus, enveloped and positive sense-RNA virus, with ∼30 kb genome ([@bib0049]). SARS-CoV-2 genome possesses a complex organization encoding various structural as well as non-structural proteins (Nsps) ([@bib0020]). Majority part of viral genome (replicase ORF1ab encompassing Nsps) is translated into two overlapping polyproteins known as pp1a and pp1ab ([@bib0003]). These polypeptides also codes for ∼306 amino acid long main protease (M^pro^) ([@bib0026]), which digests polypeptides at various conserved sites yielding 16 functional viral Nsps possessing multiple enzymatic activities especially in viral replication ([@bib0003]; [@bib0020]). One of such enigmatic protein, Nsp15, is an endoribonuclease known to be indispensable for protein interference during innate immune response ([@bib0020]). Due to functional importance of M^pro^ and Nsp15 in viral replication and survival, both could be potential therapeutic drug targets to combat COVID-19.

In addition to Nsps, SARS-CoV-2 genome also consists of structural protein encoding genes including S (spike) gene, E gene (viral envelop protein), and N (nucleo-capsid protein) gene ([@bib0018]). Viral spike proteins possess strong affinity with the human ACE2 (angiotensin-converting enzyme 2) receptor by which virus fuses with target membrane to gain entry into human cells ([@bib0012]). SARS-CoV-2 fusion potential and ACE2 affinity is much greater as compared to SARS-CoV, suggesting that the SARS-CoV-2 fusion machinery is a novel target for coronavirus fusion inhibitors. S protein binds ACE2 receptor via its S1 subunit, while its S2 subunit interacts to form fusion core, which brings viral and target cell membranes into proximity for efficient fusion and subsequent infection ([@bib0050]). Thus, SARS-CoV-2 S2 subunit could be a potential target for coronavirus fusion inhibitors. Moreover, S1 trimeric crowns removal or opening is expected to be essential for exposure of receptor binding domain (RBD) to ACE2 receptor and S2 conformational changes which enable binding and membrane fusion ([@bib0045]) suggesting that SARS-CoV-2 spike ectodomain structure and SARS-CoV-2 spike closed state glycoprotein structure might be novel therapeutic targets to develop anti-COVID-19 drugs.

Growing evidences have established the worth of polyphenols as lead compounds for drug discovery against various human diseases ([@bib0007]). Recent studies reported that polyphenol have potential to combat with COVID-19 ([@bib0002]). Caffeic acids are one of the abundant plant-based polyphenols possessing 2 phenolic hydroxyl moieties and commonly found in coffee, fruits and vegetables ([@bib0030]). Caffeic acids have been reported for their potent virucidal activity against herpes simplex virus ([@bib0023]), SFTS (severe fever with thrombocytopenia syndrome) virus ([@bib0033]), and influenza virus ([@bib0042]). Based upon these results, we have screened a library of caffeic acid derivatives (CAFDs) ([Figure 1](#fig0001){ref-type="fig"} ) for the identification of novel natural anti-COVID-19 compounds against various SARS-CoV-2 drug targets including COVID-19 M^pro^ (6LU7), SARS-CoV-2 S2 subunit (6LXT), Nsp15 endoribonuclease (6VWW), SARS-CoV-2 spike ectodomain open state structure (6VYB), and SARS-CoV-2 spike closed state glycoprotein structure (6VXX). Our results present in silico-based identification of khainaoside C, 6-O-Caffeoylarbutin, khainaoside B, khainaoside C and vitexfolin A as potent modulators of COVID-19 M^pro^, Nsp15, coronavirus fusion protein, spike open state and closed state structure respectively. Our findings will provide valuable data for exploration and development of caffeic acid-derivatives as lead structures, novel therapeutic and prophylaxis agents against COVID-19 in the near future.Figure 1Chemical structures of caffeic acid and its derivativesFigure 1

Methods {#sec0002}
=======

To obtain binding interactions between CAFDs and binding pockets of 5 different proteins of SARS-CoV-2, five independent docking analyses were performed by using Molegro Virtual Docker (MVD) software in a computer cluster system provided by EXPER, model-FQC-01266 running Intel Core i3--2100 CPU \@3.10GHz Processor, 64 BİT, 4 GB RAM, 1TB hard disk, and NVIDIA GeForce GT 630 Graphic card. The crystal structures of the following SARS-CoV-2 proteins were retrieved from the protein data bank web site (<http://www.rcsb.org/pdb>): SARS-CoV-2 M^pro^ (PDB ID: [6LU7](pdb:6LU7){#interref0003}: Resolution 2.16 Å) ([@bib0015]), Nsp15 endoribonuclease (PDB ID: [6VWW](pdb:6VWW){#interref0004}) ([@bib0021]), coronavirus fusion protein (PDB ID: [6LXT](pdb:6LXT){#interref0005}) ([@bib0050]), SARS-CoV-2 spike ectodomain (PDB ID: [6VYB](pdb:6VYB){#interref0006}) and spike glycoprotein (open state) (PDB ID: [6VXX](pdb:6VXX){#interref0007}) ([@bib0044]). The selected cavity of 6LU7 is the binding site of natural inhibitor N3. Nelfinavir, utilized for the cure of the HIV (human immunodeficiency virus), was utilized as a positive control. For other targets, the docking cavities of target proteins were selected according to the amino acids involved in the activity of protein. The docking x y z positions of the proteins were identified as-10.87 15 68.21 for 6LU7 (radius 15 Å) −68.51 29.06 29 for 6VWW (radius 14 Å), -20 19 -25 for 6LXT (radius 22 Å), 217 195 265 for 6VXX (radius 24 Å) and 231 185 168 for 6VYB (radius 21 Å). MolDock Score was selected at the scoring function and the search algorithm. After docking, energy minimization and H-bond optimizations were performed. The docking simulation was repeated for each ligand 20 times. The top binding scores were utilized for further analysis. Also, Discovery Studio Visualizer 2020 was used for in-depth analysis of docking results.

The chemical structures of selected compounds were received at 3D SDF conformer from the PubChem site. PubChem CIDs of examined compounds are given respectively; Khainaoside C (44606078), Calceolarioside B (5273567), Vitexfolin A(10458788), Calceolarioside C (45360240), Scrophuloside B (11712581), Cynarin (CYN) (5281769), Eutigoside A (10026568), Calceolarioside D (14015431), Robustaside D (38358972), Chicoric acid (CHA) (5281764), Robustaside E (50994836), Dodegranoside A (44513070), 6-O-Caffeoylarbutin (15689808), Khainaoside B (44606238), Calceolarioside A (5273566), Propyl 3-(3.4-dihydroxyphenyl)-2-\[(E)-3-(3.4-dihydroxyphenyl)prop-2-enoyl\]oxypropanoate (11956645), Dactylifric acid (6124136), Neochlorogenic acid (NCHL) (5280633), Fertaric acid (FTA) (22298372), Prenyl caffeate acid (5281790), Caftaric acid (CFT) (6440397), Chlorogenic acid (CHL) (1794427), Coutaric acid (CTA) (57517924), Caffeic acid (689043), p-Coumaric acid (637542), Ferulic acid (445858). 3D SDF structures were prepared with ChemBio3D or MarvinSketch for simple molecules.

ADME and toxicity prediction {#sec0003}
----------------------------

In silico ADME analysis was conducted to investigate physicochemical properties of potent hits, such as water solubility, lipophilicity and pharmacokinetics by using following website <http://www.swissadme.ch> ([@bib0005]). Absorption (% ABS) of potent hits from intestine was evaluated by: % ABS = 109 × (0.345xTPSA). Toxicity analysis was performed using offline software Toxtree 3.1 application ([@bib0052]).

Molecular dynamics study {#sec0004}
------------------------

The structures of the best-docked complex for each protein are selected for in-depth molecular dynamics simulation (MDS) study for a period of 20 ns. NAMD software was utilized to conduct the MDS with CHARMM 36 force field ([@bib0010]; [@bib0037]). VMD is used to prepare the complexes for the MDS ([@bib0011]). Complexes are subjected to equilibration using the CHARMM GUI web server after that a production run for 20 ns is performed on Shaheen supercomputer of King Abdullah University of Science and Technology (KAUST) under the project number k1482 ([@bib0017]). The equilibration is done on the protein-small molecule solvated in the TIP3P water model and 0.154 M NaCl solution at 310 K temperature and pH 7 ([@bib0031]). VMD is utilized in trajectories analysis, while the Chimera software of UCSF is used for cluster analysis ([@bib0031]; [@bib0036]). After trajectory clustering, the five most populous clusters are represented by a conformation and tested for its binding to the protein. AutoDock Vina software is used in the binding energy calculations using 40 Å × 40 Å × 40 Å box dimensions ([@bib0032]; [@bib0041]).

Results {#sec0005}
=======

The MolDock Scores obtained from the docking studies of CAFDs and 6LU7 are summarized in [Table 1](#tbl0001){ref-type="table"} . Based on these in-silico results, khainaoside C, calceolarioside B, vitexfolin A, calceolarioside C and scrophuloside B exhibited best binding potential with COVID-19 virus M^pro^ having MolDock scores of -191.5990, -191.2950, -186.2820, -178.5540 and -177.799 respectively. Khainaoside C showed the highest binding affinity at the active site. It forms hydrogen bond interactions with His 41, His 163, Met 165, Arg 188, Gln 192, Glu 166, Cys 145, Gly 143, Ser 144, Leu 141 ([Figure 2](#fig0002){ref-type="fig"} A). Calceolarioside B binds to SARS-CoV-2 M^pro^ by forming hydrogen bonds with His 41, His 163, His 164, Met 165, Asp 187, Gln 189, Thr 190, Arg 188, Gln 192, Glu 166, Cys 145, Gly 143, Ser 144, Leu 141 ([Figure 2](#fig0002){ref-type="fig"}A). Vitexfolin A and calceolarioside C also showed good binding affinities to the active sites of COVID-19 virus M^pro^ via interacting with Met 49, Tyr 54, Cys 44, His 163, His 164, Arg 188, Gln 192, Glu 166, Cys 145, Ser 144, Leu 141, Phe 140 ([Figure 2](#fig0002){ref-type="fig"}A) and His 41, Tyr 54, Thr 26, His 163, His 164, Met 165, Asp 187, Gln 189, Thr 190, Arg 188, Gln 192, Glu 166, Asn 142, Cys 145, Ser 144, Leu 141 respectively ([Figure 2](#fig0002){ref-type="fig"}A). According to the obtained results, khainaoside C and calceolarioside B affinities with COVID-19 virus M^pro^ and their scores are significantly higher than Nelfinavir. Ligand plot in [Figure 2](#fig0002){ref-type="fig"}B represents residual wise van der Waals interactions, pi-alkyl interactions, pi-pi interactions and pi-sulfur interactions of potent hits with M^pro^.Table 1Results of the docking of CAFDs on the crystal structure of COVID-19 virus M^pro^ (6LU7)Table 1LigandMolDock ScoreProtein-Ligand InteractionsInternal Ligand InteractionsH-Bond**Nelfinavir**-147.3800-171.69822.284-6.8731Khaınaosıde C-191.599-200.0258.42644-27.1197Calceolarioside B-191.295-192.4491.15387-29.335Vitexfolin A-186.282-195.8499.56729-27.845Calceolarioside C-178.554-230.4951.9361-26.4726Scrophuloside B-177.799-174.45-3.34965-13.1931Cynarin-177.1841-207.73730.5529-20.6951Eutıgosıde A-167.291-178.44311.1524-19.147Calceolarioside D-165.78-173.1567.37642-19.0178Robustaside D-164.794-181.85417.0598-31.946Chicoric acid-162.6854-178.75616.0706-18.3829Robustaside E-161.535-177.95116.4157-24.393Dodegranoside A-157.933-192.63334.6997-32.29336-O-Caffeoylarbutin-156.602-166.4429.84068-17.4251Khaınaosıde B-155.284-185.86730.5834-21.4445Calceolarioside A-149.67-174.02924.3592-24.5915Propyl 3-(3,4-dihydroxyphenyl)-2-\[(E)-3-(3,4-dihydroxyphenyl)prop-2\--148.144-166.58918.4446-11.8087Methyl (2R)-3-(3,4-dihydroxyphenyl)-2-\[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl\]oxypropanoate-145.999-165.94319.944-10.591Dactylifric acid,-134.2368-156.66722.4302-19.4056Neochlorogenic acid-130.0202-159.79329.7728-21.9994Fertaric acid-127.1668-144.39817.2312-12.0719Prenyl caffeate acid-122.69655-130.6027.90545-5.00251Caftaric acid-121.9308-145.02423.0932-12.1007Chlorogenic acid-119.6166-147.50327.8864-14.8102Coutaric acid-119.1713-136.21517.0437-10.6761Caffeic acid-91.5046-100.3078.80237-12.4985p-Coumaric acid-90.0385-98.93448.89594-6.95915Ferulic-78.5495-83.68035.13082-4.9909Figure 2Docking poses of caffeic acid derivatives with COVID-19 virus M^pro^**(A)** Hydrogen bonding interactions of khaınaosıde C, scrophuloside B, vitexfolin A, calceolarioside B and calceolarioside C with amino acid residues of COVID-19 virus M^pro^, **(B)** 2D view of interaction types of khaınaosıde C, scrophuloside B, vitexfolin A, calceolarioside B and calceolarioside C with surrounding amino acids of COVID-19 virus M^pro^.Figure 2

The MolDock Scores obtained from the docking studies of CAFDs and 6VWW are provided in [Table 2](#tbl0002){ref-type="table"} . 6-O-Caffeoylarbutin, dodegranoside A, calceolarioside B, scrophuloside B and calceolarioside A possess significantly good binding potential to Nsp15 endoribonuclease with MolDock Scores -171.541, -168.82, -164.77, -163.023 and -157.557 respectively as compared to Nelfinavir which possess MolDock score of -148.413 The interactions of these compounds with amino acid residues of target protein are shown in [Figure 3](#fig0003){ref-type="fig"} A. Ligand plot representing residual wise van der Waals interaction, pi-alkyl interactions, pi-cation and pi-anion interactions are presented in [Figure 3](#fig0003){ref-type="fig"}B.Table 2Results of the docking of CAFDs on the crystal structure of Nsp15 endoribonuclease (6VWW)Table 2LigandMolDock ScoreProtein-Ligand InteractionsInternal Ligand InteractionsH-Bond**Nelfinavir**-148.413-176.91828.5042-6.244526-O-Caffeoylarbutin-171.541-192.58521.0444-21.747Dodegranoside A-168.82-189.32120.5011-20.0539Calceolarioside B-164.77-178.00213.2327-16.1947Scrophuloside B-163.023-188.72825.7045-17.7Calceolarioside A-157.557-191.86634.3089-22.6471Calceolarioside D-157.531-176.71419.1827-13.5793Robustaside D-152.212-166.64914.4366-13.1528Vitexfolin A-151.664-174.55422.8901-14.0706Eutıgosıde A-150.42-173.68223.2626-14.3851Robustaside E-150.175-181.35931.1841-20.7424Chicoric acid-149.662-165.15315.4907-9.06476Propyl 3-(3,4-dihydroxyphenyl)-2-\[(E)-3-(3,4-dihydroxyphenyl)prop-2\--148.42-160.4111.9901-11.2875Khaınaosıde B-146.216-159.43113.2149-18.838Khaınaosıde C-144.449-169.29524.8469-14.338Calceolarioside C-143.258-190.2947.0315-26.9485Methyl (2R)-3-(3,4-dihydroxyphenyl)-2-\[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl\]oxypropanoate-136.959-151.08214.1226-7.66985Cynarin-136.239-168.63832.3994-9.84515Dactylifric acid-124.395-135.85311.4586-11.8072Chlorogenic acid-117.22-146.22429.004-19.2892Fertaric acid-115.811-131.07215.2609-10.3567Neochlorogenic acid (NCHL)-114.913-140.21525.3017-13.8222Prenyl caffeate acid-113.339-118.3765.03646-9.94435Coutaric acid-112.946-123.27310.3278-9.20319Caftaric acid-110.286-130.27819.9917-13.6044p-Coumaric acid-90.4353-98.56348.12807-7.41811Caffeic acid-86.1121-92.45876.34661-7.61903Ferulic acid-78.5357-83.02754.49178-4.65339Figure 3Docking poses of caffeic acid derivatives with COVID-19 virus Nsp15 endoribonuclease **(A)** Hydrogen bonding interactions of 6-O-Caffeoylarbutin, calceolarioside B, dodegranoside A, calceolarioside A and scrophuloside B with amino acid residues of virus Nsp15 endoribonuclease **(B)** 2D view of interaction types of 6-O-Caffeoylarbutin, calceolarioside B, dodegranoside A, calceolarioside A and scrophuloside B with surrounding amino acids of COVID-19 virus Nsp15 endoribonuclease.Figure 3

[Table 3](#tbl0003){ref-type="table"} presents MolDock Score, interactions and H-Bonds obtained from the docking studies of CAFDs with 6LXT. The results show highest binding potential of khaınaosıde B (-150.44), followed by chicoric acid (-150.017), vitexfolin A (-149.558) 6-O-Caffeoylarbutin (-146.12) and calceolarioside B (-141.587) as compared to Nelfinavir (-130.687). The binding interactions of potent compounds with S2 subunit of fusion protein are shown in [Figure 4](#fig0004){ref-type="fig"} A. [Figure 4](#fig0004){ref-type="fig"}B shows residual wise van der Waals interactions, pi-alkyl interactions, pi-pi interactions, amide-pi-stacked interactions and pi-anion interactions of potent hits with 6LXT.Table 3Results of the docking of CAFDs on the crystal structure of Post fusion core of SARS-CoV-2 S2 subunit (6LXT)Table 3LigandMolDock ScoreProtein-Ligand InteractionsInternal Ligand InteractionsH-Bond**Nelfinavir**-130.687-164.23233.5452-9.3432Khaınaosıde B-150.44-161.89611.4557-8.36351Chicoric acid-150.017-168.6218.603-11.1833Vitexfolin A-149.558-185.21735.6583-20.17696-O-Caffeoylarbutin-146.12-164.64118.5207-16.9512Calceolarioside B-141.587-172.32630.7394-11.9822Khaınaosıde C-139.261-147.3318.06987-11.3859Calceolarioside D-138.843-151.69712.8542-8.86834Calceolarioside A-135.155-170.65235.4964-13.9423Scrophuloside B-134.911-150.315.3891-11.735Robustaside D-132.712-148.215.488-8.16426Calceolarioside C-132.021-171.94839.9268-21.5846Cynarin-129.89-173.96244.0712-15.3668Eutıgosıde A-129.684-148.71319.0289-10.3091Dodegranoside A-129.625-153.19923.5741-8.37051Robustaside E-128.164-158.03229.8676-14.1894Propyl 3-(3,4-dihydroxyphenyl)-2-\[(E)-3-(3,4-dihydroxyphenyl)prop-2\--125.955-141.06515.1099-5Methyl (2R)-3-(3,4-dihydroxyphenyl)-2-\[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl\]oxypropanoate-120.097-139.18419.087-10.5192Neochlorogenic acid-112.361-138.54426.183-15.9721Fertaric acid-106.658-131.95825.3-9.22242Dactylifric acid-106.238-127.63521.3977-12.3803Caftaric acid-104.253-120.77916.5262-10.7807Coutaric acid-103.181-114.84911.6674-9.25386Chlorogenic acid-101.663-127.12325.4594-12.0677Prenyl caffeate acid-96.4395-106.95510.5154-7.95977p-Coumaric acid-77.652-84.37516.72302-8.07627Caffeic acid-70.7393-77.82017.08078-8.17656Ferulic-68.4726-74.52746.05481-5.1854Figure 4Docking poses of caffeic acid derivatives with COVID-19 virus fusion protein S2 subunit **(A)** Hydrogen bonding interactions of khaınaosıde B, chicoric acid, vitexfolin A, 6-O-Caffeoylarbutin, and calceolarioside B with amino acid residues of fusion protein S2 subunit **(B)** 2D view of interaction types of khaınaosıde B, chicoric acid, vitexfolin A, 6-O-Caffeoylarbutin, and calceolarioside B with surrounding amino acids of COVID-19 virus fusion protein S2 subunit.Figure 4

[Table 4](#tbl0004){ref-type="table"} shows the obtained results from the docking studies of CAFDs with crystal structure 6VYB. The results show highest binding potential of khaınaosıde C (-166.448), followed by khaınaosıde B (-165.435), and calceolarioside B (-153.135), calceolarioside C (-151.284), and calceolarioside D (-149.841) with comparison to reference drug Nelfinavir (-148.747). The amino acid residues of spike protein participating in interaction with these compounds are presented in [Figure 5](#fig0005){ref-type="fig"} A. CAFDs interact with target protein via van der Waals interactions, pi-alkyl interactions, pi-pi interactions, amide-pi-stacked interactions and pi-sigma interactions ([Figure 5](#fig0005){ref-type="fig"}B).Table 4Results of the docking of CAFDs on the crystal structure of SARS-CoV-2 spike ectodomain structure (open state) (6VYB)Table 4Ligand NameMolDock ScoreProtein-Ligand InteractionsInternal Ligand InteractionsH-Bond**Nelfinavir**-148.747-176.8928.1432-2.49896Khaınaosıde C-166.448-161.803-4.64496-8.71808Khaınaosıde B-165.435-193.84328.408-9.1829Calceolarioside B-153.135-177.19824.0631-11.6422Calceolarioside C-151.284-203.13351.8485-15.5073Calceolarioside D-149.841-171.43521.5938-6.20592Eutıgosıde A-144.298-150.7576.45875-8.94751Dodegranoside A-142.831-161.94319.1118-6.51745Vitexfolin A-142.604-173.88231.278-12.4266Chicoric acid-141.566-164.79623.2302-6.62961Propyl 3-(3,4-dihydroxyphenyl)-2-\[(E)-3-(3,4-dihydroxyphenyl)prop-2\--139.154-149.8510.6965-6.133966-O-Caffeoylarbutin-137.225-160.9623.7351-9.99943Cynarin-133.964-180.05246.0882-3.61595Robustaside D-133.688-139.8956.20761-7.9848Calceolarioside A-133.035-170.65937.6243-13.4663Robustaside E-132.278-154.03121.7532-4.63369Methyl (2R)-3-(3,4-dihydroxyphenyl)-2-\[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl\]oxypropanoate-129.816-140.55210.7361-3.44702Scrophuloside B-129.274-159.23329.959-5.75544Neochlorogenic acid-116.183-137.16320.9802-8.85752Dactylifric acid-114.666-128.19213.5263-5.90671Fertaric acid-111.217-123.58712.3705-2.53938Caftaric acid-109.539-124.9915.4504-9.02851Prenyl caffeate acid-109.296-118.7229.42623-3.47987Chlorogenic acid-108.993-132.88723.8942-8.6096Coutaric acid-103.861-113.7249.86261-2.97925p-Coumaric acid-87.9961-96.81638.82013-4.60597Caffeic acid-85.3883-91.76926.38084-7.06512Ferulic-83.9251-89.9696.04391-2.71179Figure 5Docking poses of caffeic acid derivatives with SARS-CoV-2 spike ectodomain **(A)** Hydrogen bonding interactions of khaınaosıde C, khaınaosıde B, calceolarioside B, calceolarioside C, calceolarioside D with amino acid residues of SARS-CoV-2 spike ectodomain (open state) **(B)** 2D view of interaction types of khaınaosıde C, khaınaosıde B, calceolarioside B, calceolarioside C, calceolarioside D with surrounding amino acids of SARS-CoV-2 spike ectodomain (open state).Figure 5

The binding energies obtained from the docking analysis of 6VXX with ligands are presented in [Table 5](#tbl0005){ref-type="table"} . Vitexfolin A, chicoric acid, eutıgosıde A exhibited the best potential against spike glycoproteins of SARS-CoV-2. According to in silico results, 7 of the compounds have a better affinity to bind with spike glycoproteins than Nelfinavir ([Table 5](#tbl0005){ref-type="table"}). The ligand-protein interactions are shown in [Figure 6](#fig0006){ref-type="fig"} A. Amino acid residues of 6VXX interact with CAFDs via van der Waals interaction, pi-alkyl interactions, pi-pi interactions and pi-sigma interactions are ([Figure 6](#fig0006){ref-type="fig"}B).Table 5Results of the docking of CAFDs on the crystal structure of SARS-CoV-2 spike glycoprotein (closed state) (6VXX)Table 5Ligand NameMolDock ScoreProtein-Ligand InteractionsInternal Ligand InteractionsH-Bond**Nelfinavir**-133.655-160.11726.4619-7.62916Vitexfolin A-158.443-177.85419.4111-15.769Chicoric acid-141.781-166.84225.0606-7.55396Eutıgosıde A-137.834-167.18929.3553-11.5249Scrophuloside B-136.54-169.15832.6181-10.2562Cynarin-136.457-176.33939.8825-11.3919Calceolarioside D-135.748-145.86510.1171-7.33425Khaınaosıde B-134.98-141.1676.18667-14.3158Robustaside D-130.586-154.3823.7941-12.9145Robustaside E-126.92-126.404-0.5159-14.472Khaınaosıde C-126.895-124.812-2.0832-10.5752Propyl 3-(3,4-dihydroxyphenyl)-2-\[(E)-3-(3,4-dihydroxyphenyl)prop-2\--125.712-153.82228.1099-11.792Calceolarioside A-123.256-152.37929.1231-13.9537Calceolarioside B-122.232-149.126.8684-13.69666-O-Caffeoylarbutin-121.921-116.367-5.5538-8.70194Dodegranoside A-119.728-144.49624.7679-9.47601Methyl (2R)-3-(3,4-dihydroxyphenyl)-2-\[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl\]oxypropanoate-118.965-140.46721.502-14.4652Calceolarioside C-116.478-176.58560.1073-21.2389Dactylifric acid,-111.795-132.80421.0096-3.32111Caftaric acid-106.167-121.40215.2351-12.1219Coutaric acid-105.763-118.79813.0344-11.9847Fertaric acid-104.402-115.52311.1211-9.61248Neochlorogenic acid-102.203-130.87728.6741-9.99063Prenyl caffeate acid-100.523-107.1876.66386-2.5Chlorogenic acid-92.1219-117.74725.6247-17.3432Ferulic-78.2151-82.40194.18678-0.5326Caffeic acid-75.6669-83.08297.41603-0.37606p-Coumaric acid-73.8693-82.94049.07116-6.05487Figure 6Docking poses of caffeic acid derivatives with SARS-CoV-2 spike glycoprotein (closed state) **(A)** Hydrogen bonding interactions of scrophuloside B, chicoric acid, vitexfolin A, cynarin and eutıgosıde A with amino acid residues of SARS-CoV-2 spike glycoprotein (closed state) **(B)** 2D view of interaction types of scrophuloside B, chicoric acid, vitexfolin A, cynarin and eutıgosıde A with surrounding amino acids of spike glycoprotein (closed state).Figure 6

Among all the screened compounds, only calceolarioside B possess good binding affinities with four out of five selected targets of SARS-CoV-2 (COVID-19 virus M^pro^, Fusion S2 subunit, spike ectodomain (open state), and Nsp15 endoribonuclease) while vitexfolin A exhibits good binding efficacy against three out of five selected proteins of SARS-CoV-2 (COVID-19 virus M^pro^, Fusion S2 subunit and spike protein). Based upon these findings, calceolarioside B could be regarded as pan inhibitor of SARS-CoV-2 proteins.

Relative assessment of MolDock scores were performed with (β), of CAFDs against SARS-CoV-2 proteins encoded by PDB IDs as **6LU7, 6VWW, 6TLX, *6VYB,*** and ***6VXX*** ([Figure 7](#fig0007){ref-type="fig"} ). We normalized all MolDock scores using equation as described below$$\beta_{N} = \beta_{i}/{}\beta_{\max}$$Where; *β~N~*, β~i,~ β~max~ represent the normalized MolDock score, MolDock score of a compound for any drug target protein and maximum MolDock score among all compounds of any drug target protein.Figure 7MolDock Score comparison among 27 compounds versus active sites SARS-CoV-2 6LU7, 6VWW, 6LXT, 6VYB, and 6VXX.Figure 7

ADME profiling of potent caffeic acid derivatives {#sec0006}
-------------------------------------------------

The eight compounds with high-binding affinity against COVID-19 were analysed for ADME properties using SwissADME web tool. The results of eight compounds with high activity potential are presented in [Figure 8](#fig0008){ref-type="fig"} . Eutigoside A meets all criteria for oral use. Physicochemical, pharmacokinetics and drug-likeness properties of potent hits are presented in [Table 6](#tbl0006){ref-type="table"} . All of the compounds are water soluble. They do not cross the blood brain barrier, do not interact with interaction of main enzymes of Cytochromes P450, and have P-gp substrate properties. Toxicity assessment according to the chemical structure was carried out using Toxtree software.Figure 8Bioavailability Radar related to physicochemical properties of molecules (Criterias: Lipophilicity:-0.7 \<XLOGP3\< +5.0, Size: 150 MW 500 g/mol, Polarity: 20 \<TPSA\< 130 Å2,Insolubility: 0\<log S\<6, Insaturation, Flexibility: 0.25\<rotatable bonds\<9).Figure 8Table 6ADME profiling of potent caffeic acid derivativesTable 6Compound NameGhoseTPSAAbsorption (% ABS)Water SolubilityLog *S* (ESOL)BBB permeantP-gp substrateCYP isoform interactKhaınaosıde CNo175.3748.49-3.12- SolubleNoYesNoCalceolarioside BYes186.3744.70-2.85- SolubleNoYesNoVitexfolin ANo183.2145.79-3.01- SolubleNoYesNo6-O-CaffeoylarbutinYes166.1451.68-2.86- SolubleNoYesNoKhaınaosıde BNo201.6739.42-3.14- SolubleNoYesNoDodegranoside AYes166.1451.68-2.86- SolubleNoYesNoChicoric acidYes208.1237.19-3.58- SolubleNoYesNoEutıgosıde AYes145.9158.66-3.11- SolubleNoYesNoNelfinavirNo127.2065.18-6.36-Poorly solubleNoYes1A2, 2C19, 3A4

Molecular dynamics simulation {#sec0007}
-----------------------------

[Figure 9](#fig0009){ref-type="fig"} A shows the Root Mean Square Deviation (RMSD) in Å, Radius of Gyration (RoG) in Å, and Surface Accessible Surface Area (SASA) in Å2. The values of the three parameters indicate the equilibration of the systems during the 20 ns MDS. On the other hand, [Figure 9](#fig0009){ref-type="fig"}B shows the stability of the residues during the simulation through per residue Root Mean Square Fluctuation (RMSF) in Å. Dashed-red lines indicate the positions of the active site residues. [Figure 9](#fig0009){ref-type="fig"}C shows the average binding energies obtained for the representative conformation for each cluster after the MDS run for 20 ns on the protein-ligand complexes.Figure 9Post-dynamics analysis: (A) Root Mean Square Deviation (RMSD) (blue line), Radius of Gyration (RoG) (orange line), and surface accessible surface area (SASA) (gray line) for the best complex for each viral protein during 20 ns MDS run. (B) Per-residue Root Mean Square Fluctuation (RMSF) for the same complexes with dashed lines represents the active residues. (C) Post-dynamics average binding energies (in kcal/mol) calculated for the complexes using AutoDock Vina. Error bars represent the standard deviations.Figure 9

Discussion {#sec0008}
==========

Polyphenols possess various beneficial properties against viral diseases such as modulation of immune system ([@bib0013]), inhibiting viral replication ([@bib0022]) and reduction of viral uptake by target membrane ([@bib0043]). CAFDs are polyphenolic compounds which possess prominent antiviral activity especially against hepatitis B virus (HBV) ([@bib0051]) and HIV ([@bib0038]). Keeping in view the potential of CAFDs against viral diseases ([Figure 1](#fig0001){ref-type="fig"}), 27 CAFDs were docked with 5 proteins of SARS-CoV-2 to evaluate their binding energies against these targets. Out of 27 CAFDs, 19 of them showed greater MD score (ranging between -191 to -159, [Table 1](#tbl0001){ref-type="table"}) against COVID-19 virus M^pro^ as compared to nelfinavir (-147) ([@bib0002]). 11 out of 27 CAFDs possess greater MD score against Nsp15 endoribonuclease ([Table 2](#tbl0002){ref-type="table"}) and SARS-CoV-2 fusion S2 subunit as compared to reference drug ([Table 3](#tbl0003){ref-type="table"}), while 5 were found to be good binder of spike ectodomain (open state) ([Table 4](#tbl0004){ref-type="table"}) and 7 exhibits good binding interaction with spike glycoprotein (closed state) as compared to Nelfinavir ([Table 5](#tbl0005){ref-type="table"}). From chemical point of view, the binding potential of potent CAFDs i.e., khainaoside C, scrophuloside B, vitexfolin A, calceolarioside B & C with SARS-CoV-2 proteins can largely be attributed to the presence of hydroxyl and carbonyl groups. These groups specifically --OH group serves as excellent candidate for hydrogen bonding and exhibits tendency to form strong interactions with amino acid residues of target protein. As reported in [Figure 9](#fig0009){ref-type="fig"}, the 20 ns MDS runs were enough for the protein-ligand complexes. RMSD for each system show equilibration, while SASA and RoG both show stabilities during the MDS. The per-residues RMSF profiles in [Figure 9](#fig0009){ref-type="fig"}B indicate the stability of the binding since the interacting residues (H41, C149 in Mpro, K90, T167 in NSP15, R185 in the post-fusion core, N343, Y380, G431 in spike ectodomain, and F342, T430, N437 in spike closed state) have low RMSF values in all the complexes. Additionally, the average binding energies ([Figure 9](#fig0009){ref-type="fig"}C) calculated for the different clusters during the MDS runs show that the binding is stable. Hence, the MDS study supports previous docking scores values.

Most of the CAFDs possessing good binding energies with various proteins of SARS-CoV-2 have been isolated from traditionally used medicinal plants such as: khainaoside B and khainaoside C are isolated from Thai medicinal plant *Vitex glabrata* which is traditionally used to support lactation ([@bib0028]) and possess anti-diabetic potential ([@bib0039]). Vitexfolin A is an important constituent of *Vitex rotundifolia* and possesses strong analgesic effect ([@bib0034]). Scrophuloside B has been identified in traditional Chinese medicinal plants including *Picrorhiza scrophulariiflora* ([@bib0047]) and *Radix scrophulariae* ([@bib0016]). Calceolarioside B has been isolated from *Fraxinus sieboldiana* and *Forsythia suspensea* plants both of which possess anti-inflammatory and anti-viral properties ([@bib0019]; [@bib0046]). While some of potent CAFDs are found in vegetables and fruits such as: Lettuce (*Lactuca sativa*), a widely consumed leafy vegetable, is found to be enriched with various CAFDs such as chicoric acid and chlorogenic acid ([@bib0001]). Chicoric acid has been long known as potent anti-viral agent against HIV ([@bib0025]) and its mechanism of action involves deactivation of HIV-1 integrase, increased T-lymphoblastoid viability, and downregulation of reverse transcriptase of HIV-1 ([@bib0035]). 6′-O-caffeoylarbutin is abundantly found in *Vaccinium dunalianumas. V. dunalianumas* is a commonly cultivated blueberry species in China and its dried leaf buds as herbal tea while its leaves are used as folk medicine ([@bib0024]; [@bib0029]). Sunflower (*Helianthus annuus*) sprouts (nutritious sunflower lettuce) found to be enriched with cynarin ([@bib0040]), recommending these foods as beneficial food choice for COVID-19 patients.

Among all these potent compounds, calceolarioside B is identified as pan-inhibitor of SARS-CoV-2 having potential to target SARS-CoV-2 M^pro^, Nsp15, coronavirus fusion protein, as well as spike ectodomain which brought excitement about calceolarioside B\'s potential against COVID-19. Interestingly, calceolarioside B is also an important constituent of *Akebia trifoliata* fruit which is popularized in Asia due to its nutritional values as well as delicious taste and also used as dietary supplement for its various health benefits including anti-microbial and anti-inflammation ([@bib0048]), suggesting that *Akebia trifoliata* fruit could potentially help COVID-19 patients to fight this disease. Calceolarioside B has potential to inhibit gp4l transmembrane glycoproteins of HIV (human immunodeficiency virus) ([@bib0019]). These glycoproteins play critical role in virus cell fusion with target membrane to enable viral entry into the host cell ([@bib0004]). As calceolarioside B is identified as potent binder of SARS-CoV-2 spike glycoprotein during our study, the results from both of these studies propose calceolarioside B as viral and target membrane fusion inhibitor further strengthening its role against COVID-19.

In addition, calceolarioside B exhibits good anti-RSV (respiratory syncytial virus) effects ([@bib0006]) which recommend that calceolarioside B rich foods could be a potential alternative approach for the prevention and treatment of COVID-19. In addition to its anti-viral properties, it has potential to inhibit IL-6 production to exert it anti-inflammatory properties ([@bib0014]). COVID-19 patients suffer with severe inflammatory response in the later stages of infection, thus, dual anti-viral/anti-inflammatory properties of this compound makes it ideal candidate for drug development for prevention and treatment of COVID-19. As coronaviruses mutations make it difficult to develop vaccine, so does the single-target drugs. Single-target drugs might encounter low efficacy as the virus mutates. Thus, complex diseases like COVID-19 are more likely to be alleviated or healed though simultaneous modulation of multiple targets. Based on the above discussion, in our personal opinion, efficacy of CAFDs-enriched foods against COVID-19 as well as safety suggests that their adoption in daily diets might help prevent the onset of COVID-19 in an alternative and nonpharmacological approach.

Conclusively, this study provides scientific basis for the possible utilization of CAFDs as drug leads to develop anti-COVID-19 therapeutics. Since there is an urgent and timely need to find out effective and specific anti-viral treatment for COVID-19, this study will hopefully lay the foundation to work forward on small scale studies for the determination of 1) efficacy of CAFDs in reducing viral load and shortening the infectious period, 2) optimal dosing regimen based on impact on viremia, 3) impact on antibody production, inflammatory signaling and oxidative stress in COVID-19 patients. It seems that CAFDs have better absorption and good safety profiles as many studies pointed out the better absorption of CAFDs and CAFDs are important constituent of dietary foods. However, it would be worthwhile to conduct pharmacological studies to determine whether the bioavailability of CAFDs is good enough or it is better to administer in combinations. Once we understand the best way to deal with the CAFDs, it will be a reasonable starting point for therapeutic interventions based on the pharmacokinetic and pharmacodynamic studies on CAFDs. Despite excitement about CAFD\'s potential from antiviral and anti-inflammatory researches, there is an urgent and timely need to fill the room of knowledge for validation of CAFDs potential against COVID-19.

Shaheen supercomputer of King Abdullah University of Science and Technology (KAUST) is used to perform the MDS study (under the project number k1482). We thank Dr. Bahaa Mostafa for using his computational power unit during the analysis of the MDS data.
